Open access
86
Views
70
CrossRef citations to date
0
Altmetric
Original Research
The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)
Kai-Michael Beeh1 Insaf GmbH Institut für Atemwegsforschung, Wiesbaden, GermanyCorrespondence[email protected]
, Eric Derom2 Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium
, José Echave-Sustaeta3 Servicio de Neumología, Hospital Universitario Quirón, Madrid, Spain
, Lars Grönke4 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
, Alan Hamilton5 Boehringer Ingelheim, Burlington, ON, Canada
, Dongmei Zhai6 InVentiv Health Clinical, Wilmington, DE, USA
& Leif Bjermer7 Department of Respiratory Medicine and Allergology, Lund University, Lund, Sweden
show all
Pages 193-205
|
Published online: 03 Feb 2016
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.